Advertisement
Screener

ENANTA PHARMACEUTICALS, INC (ENTA) Graph

ENTA Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $14.36M; Research and development $22.13M; Income tax $36.00K; Net income -$19.50M.
  • 2026-03-31: Revenue $17.16M; Research and development $19.44M; Income tax $7.00K; Net income -$13.09M.
  • 2025-12-31: Revenue $18.61M; Research and development $20.86M; Income tax $24.00K; Net income -$11.94M.
  • 2025-06-30: Revenue $18.31M; Research and development $27.21M; Income tax $29.00K; Net income -$18.25M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

ENTA revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Royalty$14.36MRevenue$14.36MOperating income-$17.24MResearch & development$22.13MPre-tax income-$19.46MIncome tax$36.00KNet income-$19.50M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentIncome taxNet income
2026-06-30$14.36M$22.13M$36.00K-$19.50M
2026-03-31$17.16M$19.44M$7.00K-$13.09M
2025-12-31$18.61M$20.86M$24.00K-$11.94M
2025-06-30$18.31M$27.21M$29.00K-$18.25M
2025-03-31$14.93M$28.07M-$1.30M-$22.64M
2024-12-31$16.96M$27.66M-$416.00K-$22.29M
2024-06-30$17.97M$28.74M-$395.00K-$22.66M
2024-03-31$17.05M$35.59M-$363.00K-$31.16M
2023-12-31$18.00M$36.37M-$622.00K-$33.41M
2023-06-30$18.89M$42.99M$4.22M-$39.06M
2023-03-31$17.80M$43.47M$44.00K-$37.66M
2022-12-31$23.59M$40.90M-$34.00K-$28.99M
2022-06-30$19.48M$39.09M-$447.00K-$31.70M
2022-03-31$18.72M$42.09M$0.00-$33.59M
2021-12-31$27.65M$48.55M-$36.00K-$30.11M
2021-06-30$21.62M$46.99M-$9.38M-$24.02M
2021-03-31$20.13M$41.51M$7.11M-$22.05M
2020-12-31$31.74M$36.66M-$3.29M-$8.33M
2020-09-30$23.63M(m)$10.71M-$29.34M
2020-06-30$18.65M$34.68M-$7.14M-$14.27M
2020-03-31$27.62M$32.61M-$3.92M-$6.00M
2019-12-31$52.57M$32.78M$1.50M$13.44M
2019-09-30$51.31M(m)-$486.00K$9.19M
2019-06-30$44.37M$34.46M-$866.00K$7.04M
2019-03-31$39.63M$34.16M-$3.20M$4.14M
2018-12-31$69.89M$34.88M$3.73M$26.01M
2018-09-30$67.20M(m)$8.46M$27.42M
2018-06-30$57.26M$28.49M$3.69M$20.29M
2018-03-31$44.05M$21.48M$5.37M$12.55M
2017-12-31$38.11M$17.96M$3.64M$11.69M
2017-09-30$75.93M(m)-$18.45M$36.51M
2017-06-30$7.51M$15.41M$4.10M-$8.43M
2017-03-31$8.96M$13.00M$3.56M-$5.39M
2016-12-31$10.42M$12.53M$1.54M-$4.98M
2016-09-30$12.84M(m)$826.00K-$1.80M
2016-06-30$13.98M$10.79M-$434.00K-$1.08M
2016-03-31$13.00M$9.14M-$1.55M-$1.65M
2015-12-31$48.45M$9.03M-$9.73M$26.19M
2015-09-30$14.42M(m)$1.63M$5.81M
2015-06-30$11.60M$6.25M$428.00K$2.42M
2015-03-31$57.37M$5.37M-$20.02M$28.75M
2014-12-31$77.50M$4.52M-$28.50M$42.01M
2014-09-30$2.64M(m)$48.00K-$5.04M
2014-06-30$42.05M$4.55M$15.12M$50.05M
2014-03-31$2.16M$4.72M$0.00-$5.20M
2013-12-31$893.00K$4.26M$0.00-$5.37M
2013-09-30$1.35M(m)(m)-$4.44M
2013-06-30$1.65M$4.04M(m)-$4.14M
2013-03-31$1.20M$3.70M(m)-$3.75M
2012-12-31$27.86M$4.80M(m)$21.96M
2012-09-30$1.86M(m)(m)-$4.05M
2012-06-30$2.54M$4.92M(m)-$3.50M
2012-03-31$36.56M$3.26M(m)$32.11M
2011-12-31$741.00K(m)(m)-$3.16M

Revenue and expense 6 month

Period endRevenueResearch and developmentIncome taxNet income
2026-03-31$35.77M$40.30M$31.00K-$25.03M
2025-03-31$31.89M$55.72M-$1.72M-$44.93M
2024-03-31$35.06M$71.96M-$985.00K-$64.56M
2023-03-31$41.38M$84.37M$10.00K-$66.64M
2022-03-31$46.36M$90.64M$0.00-$63.71M
2021-03-31$51.88M$78.17M$10.40M-$30.37M
2020-03-31$80.19M$65.39M-$2.42M$7.44M
2019-03-31$109.52M$69.03M$526.00K$30.16M
2018-03-31$82.16M$39.45M$9.01M$24.25M
2017-03-31$19.38M$25.53M-$5.11M-$10.37M
2016-03-31$61.45M$18.18M$11.29M$24.54M
2015-03-31$134.87M$9.89M$48.52M$70.76M
2014-03-31$3.05M$8.98M$0.00-$10.57M
2013-03-31$29.05M$8.50M(m)$18.21M
2012-03-31$37.31M$5.93M(m)$28.95M

Revenue and expense 9 month

Period endRevenueResearch and developmentIncome taxNet income
2026-06-30$50.13M$62.43M$67.00K-$44.53M
2025-06-30$50.20M$82.93M-$1.69M-$63.19M
2024-06-30$53.03M$100.70M-$1.38M-$87.22M
2023-06-30$60.27M$127.36M$4.23M-$105.71M
2022-06-30$65.84M$129.73M-$447.00K-$95.41M
2021-06-30$73.50M$125.17M-$19.79M-$54.40M
2020-06-30$98.84M$100.07M-$9.56M-$6.83M
2019-06-30$153.88M$103.49M-$340.00K$37.19M
2018-06-30$139.42M$67.93M$12.70M$44.54M
2017-06-30$26.89M$40.94M-$9.21M-$18.80M
2016-06-30$75.43M$28.96M$11.72M$23.47M
2015-06-30$146.46M$16.14M$48.09M$73.18M
2014-06-30$45.10M$13.54M-$15.12M$39.48M
2013-06-30$30.70M$12.54M(m)$14.07M
2012-06-30$39.85M$10.86M(m)$25.45M

Revenue and expense 12 month

Period endRevenueResearch and developmentIncome taxNet income
2025-09-30$65.32M$106.74M-$1.66M-$81.89M
2024-09-30$67.64M$131.48M-$1.74M-$116.05M
2023-09-30$79.20M$163.52M$2.82M-$133.82M
2022-09-30$86.16M$164.52M-$433.00K-$121.75M
2021-09-30$97.07M$174.11M-$28.58M-$79.00M
2020-09-30$122.47M$136.76M$1.15M-$36.17M
2019-09-30$205.20M$142.21M-$826.00K$46.38M
2018-09-30$206.63M$94.86M$21.16M$71.96M
2017-09-30$102.81M$57.45M$9.24M$17.71M
2016-09-30$88.27M$40.46M$10.89M$21.67M
2015-09-30$160.88M$23.19M$46.46M$78.99M
2014-09-30$47.74M$18.74M-$15.17M$34.44M
2013-09-30$32.05M$16.84M$0.00$9.63M
2012-09-30$41.71M$15.12M$0.00$21.40M
2011-09-30$41.88M$11.55M$0.00$23.31M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Emergent BioSolutions Inc. (EBS)United States$0.347B-2.43
Larimar Therapeutics, Inc. (LRMR)United States$0.344B-1.83
Vogenx, Inc. (VOGX)United States$0.355B
Benitec Biopharma Inc. (BNTC)United States$0.337B-10.08
BioAge Labs, Inc. (BIOA)United States$0.333B-11.88
BridgeBio Oncology Therapeutics, Inc. (BBOT)United States$0.320B-3.35
Evommune, Inc. (EVMN)United States$0.320B-5.10
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01
Rezolute, Inc. (RZLT)United States$0.382B-6.45
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63